William N. Malatestinic

708 total citations
53 papers, 516 citations indexed

About

William N. Malatestinic is a scholar working on Immunology, Dermatology and Economics and Econometrics. According to data from OpenAlex, William N. Malatestinic has authored 53 papers receiving a total of 516 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Immunology, 19 papers in Dermatology and 17 papers in Economics and Econometrics. Recurrent topics in William N. Malatestinic's work include Psoriasis: Treatment and Pathogenesis (39 papers), Dermatology and Skin Diseases (18 papers) and Health Systems, Economic Evaluations, Quality of Life (16 papers). William N. Malatestinic is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (39 papers), Dermatology and Skin Diseases (18 papers) and Health Systems, Economic Evaluations, Quality of Life (16 papers). William N. Malatestinic collaborates with scholars based in United States, United Kingdom and Canada. William N. Malatestinic's co-authors include Russel Burge, Mwangi J. Murage, Baojin Zhu, Orin M. Goldblum, Steven R. Feldman, Chen‐Yen Lin, Talia M. Muram, Andre B. Araujo, Andrew Blauvelt and Nianwen Shi and has published in prestigious journals such as Circulation, Gastroenterology and Annals of the Rheumatic Diseases.

In The Last Decade

William N. Malatestinic

52 papers receiving 508 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William N. Malatestinic United States 12 376 192 167 96 86 53 516
Susanne Hartz United Kingdom 11 316 0.8× 156 0.8× 101 0.6× 51 0.5× 153 1.8× 31 531
M‐A Richard‐Lallemand France 6 535 1.4× 300 1.6× 162 1.0× 73 0.8× 130 1.5× 7 620
Canelle Mazaud France 5 296 0.8× 173 0.9× 73 0.4× 30 0.3× 64 0.7× 6 390
M.I.A. Koetsier Netherlands 12 311 0.8× 176 0.9× 59 0.4× 23 0.2× 98 1.1× 14 408
Noah Agada United States 10 297 0.8× 161 0.8× 80 0.5× 47 0.5× 36 0.4× 20 431
Zarif K. Jabbar‐Lopez United Kingdom 10 217 0.6× 289 1.5× 92 0.6× 26 0.3× 41 0.5× 23 476
Klaus Strömer Germany 13 233 0.6× 290 1.5× 63 0.4× 19 0.2× 53 0.6× 35 473
L. Salgado‐Boquete Spain 10 178 0.5× 165 0.9× 36 0.2× 17 0.2× 30 0.3× 32 303
Claudia de la Cruz United States 9 160 0.4× 108 0.6× 43 0.3× 14 0.1× 23 0.3× 17 272
Marie‐Pierre Desrosiers United States 8 155 0.4× 29 0.2× 35 0.2× 131 1.4× 33 0.4× 15 491

Countries citing papers authored by William N. Malatestinic

Since Specialization
Citations

This map shows the geographic impact of William N. Malatestinic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William N. Malatestinic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William N. Malatestinic more than expected).

Fields of papers citing papers by William N. Malatestinic

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William N. Malatestinic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William N. Malatestinic. The network helps show where William N. Malatestinic may publish in the future.

Co-authorship network of co-authors of William N. Malatestinic

This figure shows the co-authorship network connecting the top 25 collaborators of William N. Malatestinic. A scholar is included among the top collaborators of William N. Malatestinic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William N. Malatestinic. William N. Malatestinic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Armstrong, April W., Álvaro González‐Cantero, Saakshi Khattri, et al.. (2024). Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies. Dermatology and Therapy. 14(4). 933–952. 2 indexed citations
2.
Armstrong, April W., Tarannum Jaleel, Joseph F. Merola, et al.. (2024). Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity. Dermatology and Therapy. 14(6). 1615–1631. 1 indexed citations
3.
Lebwohl, Mark, Bruce Strober, Amy Schrader, et al.. (2024). Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. Drugs - Real World Outcomes. 11(3). 451–464. 2 indexed citations
4.
Gottlieb, Alice B., Russel Burge, William N. Malatestinic, et al.. (2023). Achievement of the National Psoriasis Foundation Treatment Treat-to-Target Goals in the US Ixekizumab Customer Support Program. SKIN The Journal of Cutaneous Medicine. 7(3). s201–s201. 2 indexed citations
5.
Gottlieb, Alice B., Russel Burge, William N. Malatestinic, et al.. (2023). 43015 Ixekizumab real-world effectiveness at 24 weeks in patients with psoriasis: Data from the United States Taltz Customer Support Program. Journal of the American Academy of Dermatology. 89(3). AB185–AB185. 1 indexed citations
6.
Gottlieb, Alice B., Russel Burge, William N. Malatestinic, et al.. (2023). Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program. Dermatology and Therapy. 13(8). 1831–1846. 4 indexed citations
7.
Lockshin, Benjamin, Ryan W. Harrison, Robert R. McLean, et al.. (2022). Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry. Dermatology and Therapy. 12(12). 2797–2815. 6 indexed citations
8.
9.
10.
Boytsov, Natalie, et al.. (2021). The current treatment landscape in adult atopic dermatitis in the United States: results from a cross-sectional real-world study. Journal of Dermatological Treatment. 33(3). 1707–1717. 6 indexed citations
11.
Blauvelt, Andrew, Nianwen Shi, Russel Burge, et al.. (2020). <p>Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab</p>. Patient Preference and Adherence. Volume 14. 517–527. 22 indexed citations
12.
Korman, Neil J., William N. Malatestinic, Orin M. Goldblum, et al.. (2020). Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient’s perspective. Journal of Dermatological Treatment. 33(2). 733–739. 11 indexed citations
13.
Orbai, Ana‐Maria, Julie Birt, Elizabeth Holdsworth, et al.. (2020). Impact of Enthesitis on Psoriatic Arthritis Patient-Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey. Rheumatology and Therapy. 7(4). 937–948. 7 indexed citations
14.
Leonardi, Craig L., Solmaz Setayeshgar, Sisi Wang, et al.. (2020). 14216 Long-term treatment effects of ixekizumab among psoriasis patients who achieved early high-level treatment outcomes in a real-world setting: Results from a single US dermatology referral practice. Journal of the American Academy of Dermatology. 83(6). AB133–AB133. 2 indexed citations
15.
Murage, Mwangi J., Vanita Tongbram, Steven R. Feldman, et al.. (2018). Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Preference and Adherence. Volume 12. 1483–1503. 108 indexed citations
16.
Malatestinic, William N., Beth Nordstrom, Jashin J. Wu, et al.. (2017). Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials. Journal of Managed Care & Specialty Pharmacy. 23(3). 370–381. 16 indexed citations
17.
Sawah, S. Al, Shonda A. Foster, Orin M. Goldblum, et al.. (2017). Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. Journal of Medical Economics. 20(9). 982–990. 34 indexed citations
18.
Foster, Shonda A., Baojin Zhu, Jiaying Guo, et al.. (2016). Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis. Journal of Managed Care & Specialty Pharmacy. 22(4). 396–405. 22 indexed citations
19.
Ernst, Frank R., William N. Malatestinic, & Walter T. Linde‐Zwirble. (2006). Evaluating the clinical and financial impact of severe sepsis with Medicare or other administrative hospital data. American Journal of Health-System Pharmacy. 63(6). 575–581. 9 indexed citations
20.
Braun, LeeAnn, et al.. (2003). A Sepsis Review. Dimensions of Critical Care Nursing. 22(3). 117–124. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susanne Hartz Breakdown of academic impact, for papers by M‐A Richard‐Lallemand Breakdown of academic impact, for papers by Canelle Mazaud Breakdown of academic impact, for papers by M.I.A. Koetsier Breakdown of academic impact, for papers by Noah Agada Breakdown of academic impact, for papers by Zarif K. Jabbar‐Lopez Breakdown of academic impact, for papers by Klaus Strömer Breakdown of academic impact, for papers by L. Salgado‐Boquete Breakdown of academic impact, for papers by Claudia de la Cruz Breakdown of academic impact, for papers by Marie‐Pierre Desrosiers
Rankless by CCL
2026